

Basilea pharma - Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL!

<https://marketpublishers.com/r/B870798E8A9EN.html>

Date: September 2013

Pages: 5

Price: US\$ 140.00 (Single User License)

ID: B870798E8A9EN

Abstracts

Basilea pharma (BSLN) along with its partner, Astellas is co-developing antifungal Isavuconazole (PhIII) for invasive fungal infections. Isavuconazole demonstrated non-inferiority vs. voriconazole in its international PhIII, SECURE trial in pts (n = 516) with invasive fungal disease caused by *Aspergillus* species or certain other filamentous fungi. Both intravenous (IV) and oral formulation of Isavuconazole offer flexible dosing options, in addition to a broad spectrum of activity and thus, it may offer potential benefits over the current gold standard (Vfend, Cancidas). With an increasing rate of serious infections and resistance to current drugs, we. For more detail, please read our report, released on 30th Sept., 2013 on BSLN, titled, 'Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL! '

I would like to order

Product name: Basilea pharma - Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL!

Product link: <https://marketpublishers.com/r/B870798E8A9EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B870798E8A9EN.html>